A role for cyclooxygenase-2 in ultraviolet light-induced skin carcinogenesis

Molecular Carcinogenesis

Volumn 46, Issue 8, 2007, Pages 692-698

  Rundhaug, Joyce E ^a   Mikulec, Carol ^a   Pavone, Amy ^a   Fischer, Susan M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

COX 2; EP receptors; Prostaglandin E2; Skin cancer; UV

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2;

CONFERENCE PAPER; DNA DAMAGE; EDEMA; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; EPIDERMIS HYPERPLASIA; HUMAN; INFLAMMATION; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION CARCINOGENESIS; SKIN CANCER; SKIN CARCINOGENESIS; TRANSGENIC MOUSE; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; HUMANS; NEOPLASMS, RADIATION-INDUCED; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

MUS; MUS MUSCULUS;

EID: 34547876147     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20329     Document Type: Conference Paper

References (37)

1. Boukamp P. Non-melanoma skin cancer: What drives tumor development and progression? Carcinogenesis 2005;26:1657-1667.
2. Bowden GT. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat Rev Cancer 2004;4:23-35.
3. Mitchell DL, Greinert R, de Gruijl FR, et al. Effects on chronic low-dose ultraviolet B radiation on DNA damage and repair in mouse skin. Cancer Res 1999;59:2875-2884.
4. Lu Y-P, Lou Y-R, Yen P, Mitchell D, Huang M-T, Conney AH. Time course for early adaptive responses to ultraviolet B light in the epidermis of SKH-1 mice. Cancer Res 1999;59:4591-4602.
5. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994;372:773-776.
6. Berg RJW, van Kranen HJ, Rebel HG, et al. Early p53 alterations in mouse skin carcinogenesis by UVB radiation: Immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. Proc Natl Acad Sci USA 1996;93:274-278.
7. Rebel H, Mosnier LO, Berg RJW, et al. Early p53-positive foci as indicators of tumor risk in ultraviolet-exposed mice: Kinetics of induction, effects of DNA repair deficiency, and p53 heterozygosity. Cancer Res 2001;61:977-983.
8. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: Implications for therapeutic approaches. Photochem Photobiol 2002;76:73-80.
9. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: Evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000;86:667-671.
10. Pentland AP, Schoggins JW, Scott GA, Khan KNM, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999;20:1939-1944.
11. Funk CD. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 2001;294:1871-1875.
12. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer. Carcinogenesis 1998;19:723-729.
13. 2 synthesis by human epidermoid carcinoma cells. J Invest Dermatol 1993;101:528-531.
14. Tripp CS, Blomme EAG, Chinn KS, Hardy MM, LaCelle P, Pentland AP. Epidermal COX-2 induction following ultraviolet irradiation: Suggested mechanism for the role of COX-2 inhibition in photoprotection. J Invest Dermatol 2003;121:853-861.
15. Han JA, Kim J-I, Ongusaha PP, et al. p53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J 2002;21:5635-5644.
16. 2 in human colon cancer cells. Cancer Res 1998;58:362-366.
17. Gao X, Hagmann W, Zacharek A, et al. Eicosanoids, cancer metastasis, and gene regulation: An overview. Adv Exp Med Biol 1997;400:545-555.
18. Wilgus TA, Ross MS, Parrett ML, Oberyszyn TM. Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins Other Lipid Mediat 2000;62:367-384.
19. Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM. Inhibition of cutaneous ultraviolet B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog 2003;38:49-58.
20. Fischer SM, Lo H-H, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999;25:231-240.
21. Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 2005;53:966-972.
22. Wilgus TA, Koki AT, Zweifel BS, Rubal PA, Oberyszyn TM. Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Mol Carcinog 2003;38:33-39.
23. Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006;98:736-747.
24. Tjiu J-W, Liao Y-H, Lin S-J, et al. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol 2006;126:1143-1151.
25. Akunda JK, Chun K-S, Sessoms AR, Lao H-C, Fischer SM, Langenbach R. Cyclooxygenase-2 deficiency increases epidermal apoptosis and impairs recovery following acute UVB exposure. Mol Carcinog 2007;46, DOI: 10.1002/mc.20290, in press.
26. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-482.
27. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalitiess and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-409.
28. Pentland AP, Scott G, VanBuskirk J, Tanck C, LaRossa G, Brouxhon S. Cyclooxygenase-1 deletion enhances apoptosis but does not protect against ultraviolet light-induced tumors. Cancer Res 2004;64:5587-5591.
29. Fischer SM, Pavone A, Mikulec C, Langenbach R, Rundhaug JE. Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. Mol Carcinog 2007;46, DOI: 10.1002/mc.20284, in press.
30. Bol DK, Rowley RB, Ho C-P, et al. Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res 2002;62:2516-2521.
31. Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 2002;68-69:535-556.
32. 2, in adult human epidermis. J Invest Dermatol 2005;124:965-970.
33. 1 receptor in cutaneous UVB-induced inflammation and tumor development. J Invest Dermatol 2006;126:205-211.
34. Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 2005;65:9304-9311.
35. 3 subtypes. Biochim Biophys Acta 1998;1401:221-234.
36. Lee JL, Kim A, Kopelovich L, Bickers DR, Athar M. Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer. J Invest Dermatol 2005;125:818-825.
37. 2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors. Lab Invest 2007;87:49-55.